Cleveland Biolabs Inc. (CBL) is a biotech company that develops drugs for cancer threatment and protection from radiation. New therapeutic concepts of CBL’s scientific founder, Dr. Andrei Gudkov, combined with a new source of pharmaceutical substances and strong expertise in cancer biology form the proprietary technological foundations of CBL. CBL’s institutional founders, Cleveland Clinic Foundation (CCF) and ChemBridge Corp., provide critical intellectual property and unique technical capabilities to support ongoing drug development efforts. CBL's technological pipeline is suited for the development of new pharmaceuticals and their rapid preclinical evaluation. These pharmaceuticals include: